Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > JNJ & Liver Cancer
View:
Post by pelaboost on Sep 09, 2023 7:21am

JNJ & Liver Cancer

@ dude on ST

in re your post about hepatitis c and liver cancer.

Many years ago a respected UK group suggested reolysin, now known as pela, SHOULD, not could, be used in Africa to fight liver cancer. That went nowhere. as ONC was likely trying to stay focussed on limited funds just as now.

I am quite certain of the above but I cannot find the article, and I dare say not overly important as time is not on our side.



The time to put up has arrived.



Comment by pelaboost on Sep 09, 2023 7:25am
forgot to mention JNJ among others has, or did have an interest in liver cancer. MM is also still very much a part of the puzzle. Nevertheless the chess clock is just about to run out.
Comment by pelaboost on Sep 09, 2023 7:42am
I thought I remembered that Roche and HCC were a thing. They are. Roche and ONC/Y seem to be very well matched indeed. Could there be a language barrier? Has it do do with money? Patients and shareholders would like to know!
Comment by fox7mf on Sep 09, 2023 9:03am
All good pts. Clock is ticking...pull the trigger Oncy, an acquisition is long overdue. 
Comment by Lesalpes29 on Sep 09, 2023 9:32am
Let's go Matt and management do what is to be done in the coming week. Shorts and MM are ready to put a lot of pressure on the SP if you miss again!
Comment by venture009 on Sep 09, 2023 10:53am
I remember the same re reo's effectiveness on liver cancer. There was a story about a British man with liver cancer that had tried every available treatment and nothing worked until he went on reo. As I recall it was almost a total cure. During this period the British were doing a lot of testing with reo on many different cancers. This is where H&N was first showing such promise. I wonder ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities